Aytu BioPharma, Inc. - Common Stock (AYTU)

2.6550
-0.0050 (-0.19%)
NASDAQ · Last Trade: Nov 18th, 3:09 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close2.660
Open2.650
Bid2.650
Ask2.660
Day's Range2.650 - 2.660
52 Week Range1.750 - 3.065
Volume340,662
Market Cap14.78M
PE Ratio (TTM)-1.492
EPS (TTM)-1.8
Dividend & YieldN/A (N/A)
1 Month Average Volume284,827

Chart

About Aytu BioPharma, Inc. - Common Stock (AYTU)

Aytu Biopharma Inc is a biopharmaceutical company focused on developing and commercializing innovative healthcare solutions, particularly in the fields of urology and endocrinology. The company aims to address unmet medical needs through its diverse portfolio of products and therapeutic options. Aytu leverages its expertise in research and development to bring forward new treatments that enhance patient outcomes and improve quality of life. Through strategic partnerships and a commitment to advancing science, the company seeks to deliver impactful therapies that drive meaningful change in the healthcare landscape. Read More

News & Press Releases

Halper Sadeh LLC is Investigating Whether AYTU, RPID, TRMK, ICMB are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 
By Halper Sadeh LLC · Via GlobeNewswire · November 18, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)
BALA CYNWYD, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · November 17, 2026
AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.
AYTU shareholders will receive just $2.70 per share in a tender offer transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
By Ademi LLP · Via GlobeNewswire · November 17, 2026
AYTU Stock Alert: Halper Sadeh LLC is Investigating Whether Aytu BioPharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Aytu BioPharma, Inc. (NASDAQ: AYTU) to Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share.
By Halper Sadeh LLC · Via Business Wire · November 16, 2026
Aytu BioPharma (NASDAQ:AYTU) Q1 Beat and $2.70 Cash Merger With Rosemont Reshape Outlookchartmill.com
Via Chartmill · November 16, 2026
Aytu BioPharma Inc. (NASDAQ:AYTU) Shares Jump 125% on Q4 Beat and Strong EXXUA Launchchartmill.com
Via Chartmill · September 22, 2026
Aytu BioPharma (NASDAQ:AYTU) Surges 23% as EXXUA Launch Gains Early Traction in Mixed Q3 Resultschartmill.com
Via Chartmill · May 13, 2026
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costschartmill.com
Via Chartmill · February 3, 2026
Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results
By Aytu BioPharma, Inc. · Via ACCESS Newswire · November 16, 2026
Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
GREENVILLE, S.C. and LEEDS, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), a global specialty pharmaceutical company focused on designing and delivering medicines around patients’ needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc. (“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases.
By Rosemont Pharmaceuticals · Via GlobeNewswire · November 16, 2026
Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per shareTender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to the closing price on November 13, 2026Tender offer support agreements secured from Nantahala Capital Management, Stonepine Capital Management and Aytu's directors and officersClosing is anticipated to occur by the end of calendar year 2026, subject to the satisfaction or waiver of the conditions to the tender offer
By Aytu BioPharma, Inc. · Via ACCESS Newswire · November 16, 2026
Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
DENVER, CO / ACCESS Newswire / November 10, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2027 first quarter after the market close on Monday, November 16, 2026. The Company has scheduled a conference call and webcast that same day, Monday, November 16, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
By Aytu BioPharma, Inc. · Via ACCESS Newswire · November 10, 2026
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026$26.3 million cash balance at June 30, 2026Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time
By Aytu BioPharma, Inc. · Via ACCESS Newswire · September 22, 2026
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
By Aytu BioPharma, Inc. · Via ACCESS Newswire · September 16, 2026
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.
Via ACCESS Newswire · June 1, 2026
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Via ACCESS Newswire · May 18, 2026
Aytu (AYTU) Q3 2026 Earnings Transcriptfool.com
Aytu (AYTU) Q3 2026 Earnings Transcript
Via The Motley Fool · May 13, 2026
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates
Via ACCESS Newswire · May 13, 2026
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Via ACCESS Newswire · May 6, 2026
Aytu BioPharma AYTU Q2 2026 Earnings Transcriptfool.com
Aytu BioPharma AYTU Q2 2026 Earnings Transcript
Via The Motley Fool · February 3, 2026
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Total net revenue of $15.2 million
Via ACCESS Newswire · February 3, 2026
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day was conducted both in-person and via webcast.
Via ACCESS Newswire · January 20, 2026
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs
Via ACCESS Newswire · January 20, 2026
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.
Via ACCESS Newswire · January 13, 2026
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day will be both in-person and available to view via webcast.
Via ACCESS Newswire · January 12, 2026